Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658528 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1061

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease (GERD)

Interventions

DRUG: Rabeprazole sodium
DRUG: Esomeprazole

Sponsor

Eisai Inc.